Clinical Trial

Glutamate Inhibitors in Glioblastoma

Study acronym: GLUGLIO
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 10, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this 1:1 randomized, multi-center, open-label phase Ib/II clinical trial is to explore the efficacy of the add-on of the anti-glutamatergic drugs gabapentin, sulfasalazine and memantine to standard chemoradiotherapy with temozolomide compared to chemoradiotherapy alone in patients with newly diagnosed glioblastoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-15; most recent amendment 2024-05-08.
Status change: Not Yet Recruiting → Recruiting 2023-03-21
Trial Details
NCT Number NCT05664464
Lead Sponsor University of Zurich
Collaborators: Swiss National Science Foundation
Conditions Glioblastoma
Enrollment 120 participants
Start Date 2023-01-01
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-05-10